Prospective Grant of Exclusive License: Treatment of Cardiovascular Conditions With Nitrite Therapy

Samenvatting

This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is contemplating the grant of an exclusive license to practice the invention embodied in PCT patent applications PCT/US2004/21985 and PCT/US2004/22232, filed July 9, 2004, both entitled "Use of Nitrite Salts for the Treatment of Cardiovascular Conditions" [HHS Reference Number: E-254-2003/2-3-PCT- 01], to Hope Medical Enterprises, Inc., dba Hope Pharmaceuticals TM , an Arizona S-Corporation having a principle place of business in Scottsdale, Arizona. The field of use may be limited to the use of nitrite salts for the treatment of cerebral vasospasm following subarachnoid hemorrhage and/or cardiovascular conditions. The United States of America is an assignee of the patent rights in these inventions.